A protease is an enzyme molecule that catalyses proteolysis which is the process of the breakdown of proteins into smaller polypeptides or single amino acids. A protease inhibitor molecule is used to inhibit the functioning of a protease. Antiretroviral protease inhibitors are drugs designed to treat diseases such as HIV. They block the activity of the enzyme, HIV Protease, that HIV uses in order to multiply.
Global antiretroviral protease inhibitors market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The primary factor for the growth of the market can be attributed to increasing prevalence of diseases such as HIV and HCV. Extensive research and development activities in the field of HIV treatment using protease inhibitors coupled with the rising awareness of antiretroviral therapy is expected to boost the market growth.
The market is further segmented by mechanism of action, disease indication, distribution channel, end user, and region. On the basis of mechanism of action, market is further sub-segmented into serine protease inhibitors, cysteine protease inhibitors, amino peptidase inhibitor, aspartic protease inhibitors, metallo-protease inhibitors, and others. Serine protease inhibitor segment leads the market and it is anticipated to drive the growth for antiretroviral drugs in the market on the back of its effectiveness in the treatment.
The high prevalence of diseases such as HIV and HCV has increased the demand for drugs in hospitals and diagnostic centres. Moreover, with the increasing popularity of online pharmacies the supply chain in the field of drug delivery is expected to improve tremendously. On the back of these factors the global antiretroviral protease inhibitor market is expected to grow notably over the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
Protease inhibitors are being used in various fields now-a-days. They are used in research for clinical application, drugs for treatment of diseases such as HIV/AIDS and Hepatitis C and others. On the back of this increasing product appeal antiretroviral protease inhibitors are anticipated to fuel the market growth in the forecast period.
Antiretroviral protease inhibitors are major drugs in the treatment of diseases such as HIV and HCV. With the increasing number of cases coupled with high prevalence of these diseases the demand for these drugs are bound to increase as well. Thereby, it is anticipated that the market for antiretroviral protease inhibitor will show significant CAGR over the forecast period.
Antiretroviral protease inhibitors have side effects and unbearable toxicity and hence people hesitate in using these drugs. So there is a challenge in-front of drug manufacturing companies to innovate and prepare drug which have either no side effects or they have only a few non-severe side effects.
In an effort to protect public from harmful drug effects, governments make rule and regulations stringent. Usually government regulations make product development more expensive. Such environment can create a hindrance in the market growth in that region.
From the time of research and development to the official launch of drugs, it takes a very long time. Even after development and successful trials, approval from regulatory authority takes a lot of time and a lot of entrepreneurs and big players do not invest in drug manufacturing due to this reason. Over the forecast period this may hamper the growth of injectable drug for type 2 diabetes market.
Our in-depth analysis of the global antiretroviral protease inhibitors market includes the following segments:
On the basis of regional analysis, the global antiretroviral protease inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
North American region is anticipated to dominate the global protease inhibitors market, during the forecast period owing to increasing cases of HIV and chronic HCV, growing industrial sector, and advanced health care infrastructure in the region. Asia Pacific region is expected to register the maximum CAGR during the forecast period, owing to factors such as rising health care expenditure and increasing focus of global pharmaceutical companies on Asia Pacific region. Rise in awareness about the antiretroviral diseases in the Asian and African region will drive the growth of the market.
The antiretroviral protease inhibitors market is further classified on the basis of region as follows:
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization